UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034517
Receipt number R000036865
Scientific Title Intra-articular platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
Date of disclosure of the study information 2018/11/01
Last modified on 2019/10/22 17:02:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Intra-articular platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

Acronym

Platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population

Scientific Title

Intra-articular platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

Scientific Title:Acronym

Platelet-rich plasma injections for the patients with osteoarthritis of the knee in the Japanese population

Region

Japan


Condition

Condition

Osteoarthritis of the knee

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the effectiveness of intra-articular platelet-rich plasma injections with intra-articular saline injection as a placebo for the patients with osteoarthritis of the knee

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II,III


Assessment

Primary outcomes

The improvement rate of WOMAC (Western Ontario and McMaster Universities Osteoarthritis) score in comparison between 24 weeks after the start of treatment and before treatment

Key secondary outcomes

1. Visual Analogue Scale for pain after 24 weeks from the start of treatment (at the time of the first injection)
2. The improvement rate of MRI Osteoarthritis Knee Score (MOAKS)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration

Institution is considered as a block.

Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Intra-articlar injections: Platelet-rich plasma derived from autologous peripheral blood

Interventions/Control_2

Intra-articlar injections: Saline

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1. With a history of chronic (for at least 3 months) knee joint pain more than 35-mm on 0- to 100-mm visual analogue scale
2. Radiographically documented grades 1-3 osteoarthritis of the knee, grade according to the Kellgren-Lawrence radiographic classification scale
3. With hydrarthrosis or bone marrow lesion or synovitis
4. Requiring infiltration in monolateral knee
5. Possibility for observation during follow-up period

Key exclusion criteria

1. BMI less than 18.5
2. BMI more than 25
3. Suffering from polyarticular disease
4. Valgus knee and varus knee more than 10 degree in X-ray
5. Previous knee arthroscopy within 6 months
6. HA or steroid intra-articular infiltration within last 1 month
7. Past history of infectious disease
8. Skin disease in knee
9. Compromised host
10. Systemic autoimmune disease
11. Anemia with hemoglobin under 9.0 g/dl
12. Blood disorders
13. Treatment with anticoagulant drugs (Aspirin, Warfarin)
14. Having undergone treatment with steroids during 3 months before inclusion in this study
15. Treatment with NSAIDs during 2 weeks before its inclusion in this study
16. Patients who had malignancy during 5 years before inclusion in this study
17. Patients who cannot have a consent with document
18. Patients whom the doctor has determined that it is not suitable for this clinical study

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Masashi
Middle name
Last name Yamazaki

Organization

University of Tsukuba

Division name

Department of Orthopaedic Surgery, Faculty of Medicine

Zip code

3058575

Address

1-1-1 Tennodai, Tsukuba, Ibaraki

TEL

029-853-3219

Email

masashiy@md.tsukuba.ac.jp


Public contact

Name of contact person

1st name Tomokazu
Middle name
Last name Yoshioka

Organization

University of Tsukuba

Division name

Div. of Regenerative Med. for Musculoskeletal System, Dep. of Orthop. Surgery, Faculty of Medicine

Zip code

3058575

Address

1-1-1 Tennodai, Tsukuba, Ibaraki

TEL

029-853-3219

Homepage URL


Email

yoshioka@md.tsukuba.ac.jp


Sponsor or person

Institute

University of Tsukuba Hospital

Institute

Department

Personal name



Funding Source

Organization

Department of Orthopaedics Surgery, Faculty of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Japanese Association for the Promotion of State-of-the-Art in Medicine

Address

13-8 Takamine-cho, Showa-ku Nagoya-shi, Aichi 466-1811, Japan

Tel

052-745-6881

Email

tokutei-nintei@japsam.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 10 Month 31 Day

Date of IRB

2018 Year 01 Month 25 Day

Anticipated trial start date

2018 Year 11 Month 01 Day

Last follow-up date

2022 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 10 Month 16 Day

Last modified on

2019 Year 10 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036865


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name